Prime Medicine (PRME) Share-based Compensation (2021 - 2026)

Prime Medicine (PRME) has 6 years of Share-based Compensation data on file, last reported at $4.6 million in Q1 2026.

• Quarterly Share-based Compensation fell 18.25% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 396.94% YoY) and the FY2025 annual result came in at $29.3 million, down 34.87% from the prior year.
• Share-based Compensation grew to $4.6 million in Q1 2026, from -$54.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $78.1 million in Q2 2025 to a low of -$54.5 million in Q4 2025.
• A 5-year average of $7.9 million and a median of $5.0 million in 2023 frame the typical range for Share-based Compensation.
• The widest YoY moves for Share-based Compensation: up 650.18% in 2024, down 700.97% in 2024.
• Tracing PRME's Share-based Compensation over 5 years: stood at $24.7 million in 2022, then slumped by 125.16% to -$6.2 million in 2023, then surged by 608.93% to $31.6 million in 2024, then sank by 272.24% to -$54.5 million in 2025, then surged by 108.52% to $4.6 million in 2026.
• The last three Share-based Compensation figures came in at $4.6 million (Q1 2026), -$54.5 million (Q4 2025), and $78.1 million (Q2 2025), per Business Quant data.